Author's posts
Amazon’s Clinics Join U.S. Employer Push Into Worksite Healthcare
Amazon’s worksite health clinics join one-third of large U.S. employers already offering a medical clinic to their employees, Mercer data shows.
How Retail Mental Health Could Be Medicine’s Next Frontier
Retail mental health clinics and urgent care centers are beginning to emerge across the U.S.
Google Bets $375M On Medicare Advantage With Oscar Health Investment
Google-parent Alphabet plans to invest $375 million into Oscar Health to help the insurer expand into the Medicare Advantage business.
To Keep You Healthy, Health Insurers May Soon Pay Your Rent
Health insurers Anthem, Aetna, Humana and UnitedHealth Group are investing in housing, mental health counseling and even food to address “social determinants of health.”
Carl Icahn Backs Off Cigna-Express Scripts Deal
Billionaire investor Carl Icahn now says he will support Cigna’s proposed purchase of Express Scripts, citing recommendations of two influential proxy advisors who came out in favor of the merger.
Obamacare Repeal A GOP Albatross As Midterm Elections Near
Democrats are hanging the Republican effort to repeal Obamacare around the necks of GOP Congressional candidates in this fall’s midterm elections.
Ample Partners For Rite Aid After End To Albertsons Deal
Rite Aid has ample opportunities to partner with health insurers and grow its EnvisionRx PBM into new Medicare Part D markets following the decision to end its merger with Albertsons.
CVS-Aetna Deal Nears Antitrust OK As Drug Plan Divestitures Loom
CVS Health executives appear confident the acquisition of Aetna will survive antitrust scrutiny though there may be divestitures where the two sell overlapping Medicare drug coverage.
Rite Aid And Albertsons Abort Merger On Eve Of Shareholders Vote
Rite Aid and Albertsons are terminating their merger agreement, the companies disclosed Wednesday night.
Amid Scrutiny, CVS Says Its PBM Retains Just 2% Of Drug Rebates
CVS Health said its retained share of rebates negotiated with drug makers this year comes to 2%, which translates to $300 million or 3% of the company’s annual earnings per share.
